^
    Home
     > 
    Drug Response
    No biomarker
    Prostate Cancer
    enzalutamide
    Sensitive
    :
    A1
    PharmaTimes -
    No biomarker
    Urothelial Cancer
    avelumab
    Sensitive
    :
    A1
    Pharmafile - 2d
    PALB2 mutation
    Pancreatic Cancer
    rucaparib
    Sensitive
    :
    C2
    J Clin Oncol - 2d
    EGFR mutation + PD-L1 overexpression
    NSCLC
    EGFR inhibitor
    Sensitive
    :
    C3
    World J Surg Oncol - 4d
    No biomarker
    NSCLC
    durvalumab + CP-675206
    Sensitive
    :
    B
    AstraZeneca Press Release - 5d
    BRCA2 mutation
    Solid Tumor
    Immunotherapy
    Sensitive
    :
    C1
    JAMA - 5d
    KDR C482R
    Clear Cell Renal Cell Carcinoma
    crizotinib + pazopanib
    Sensitive
    :
    C3
    Onco Targets Ther - 5d
    ALK R1209Q
    Colon Cancer
    crizotinib + pazopanib
    Sensitive
    :
    C3
    Onco Targets Ther - 5d
    MET N375S
    Salivary Gland Cancer
    crizotinib + pazopanib
    Sensitive
    :
    C3
    Onco Targets Ther - 5d
    BRCA2 mutation + TMB-L
    Solid Tumor
    Immunotherapy
    Sensitive
    :
    C3
    JAMA Netw Open - 5d
    STRN-ALK fusion
    NSCLC
    crizotinib
    Sensitive
    :
    C4
    Thorac Cancer - 5d
    EGFR exon 19 deletion + T790M + C797S + HER-2 amplification
    LUAD
    afatinib + rivoceranib
    Sensitive
    :
    C4
    Onco Targets Ther - 5d
    STRN-ALK fusion
    NSCLC
    alectinib
    Resistant
    :
    C4
    Thorac Cancer - 5d
    No biomarker
    Endometrial Cancer
    pembrolizumab + lenvatinib
    Sensitive
    :
    A1
    Merck (MSD) Press Release - 6d
    No biomarker
    RCC
    pembrolizumab + lenvatinib
    Sensitive
    :
    B
    Merck (MSD) Press Release - 6d
    No biomarker
    Prostate Cancer
    apalutamide
    Sensitive
    :
    A1
    J Clin Oncol - 1wk
    No biomarker
    Urothelial Cancer
    nivolumab
    Sensitive
    :
    A1
    Bristol-Myers Squibb Press Release - 1wk
    EGFR mutation
    NSCLC
    EGFR inhibitor
    Sensitive
    :
    A2
    Oncol Res Treat - 1wk
    HER-2 negative
    HER2 Negative Breast Cancer
    bevacizumab
    Sensitive
    :
    A2
    ESMO-BC 2021 - 1wk
    ER positive
    HER2 Negative Breast Cancer
    palbociclib
    Sensitive
    :
    B
    ESMO-BC 2021 - 1wk
    HIF1A overexpression
    HER2 Negative Breast Cancer
    albumin-bound paclitaxel
    Sensitive
    :
    B
    ESMO-BC 2021 - 1wk
    BACH1 overexpression
    HER2 Negative Breast Cancer
    albumin-bound paclitaxel
    Sensitive
    :
    B
    ESMO-BC 2021 - 1wk
    ER positive
    HER2 Negative Breast Cancer
    letrozole
    Sensitive
    :
    C2
    ESMO-BC 2021 - 1wk
    ER positive
    HER2 Negative Breast Cancer
    ribociclib
    Sensitive
    :
    C2
    ESMO-BC 2021 - 1wk
    HR positive
    HER2 Negative Breast Cancer
    eribulin mesylate
    Sensitive
    :
    C2
    ESMO-BC 2021 - 1wk
    HER-2 positive
    Solid Tumor
    RC48
    Sensitive
    :
    C2
    Gastric Cancer - 1wk
    CIP2A-H
    CML
    dasatinib
    Resistant
    :
    C3
    Cancers (Basel) - 1wk
    dMMR/MSI-H + TMB-L
    Pancreatic Cancer
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    dMMR/MSI-H + TMB-L
    Cholangiocarcinoma
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    dMMR/MSI-H + TMB-L
    CRC
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    dMMR/MSI-H + TMB-L
    Gastric Cancer
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    Pancreatic Cancer
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    Cholangiocarcinoma
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    CRC
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    Gastric Cancer
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    FOLR1 expression
    Solid Tumor
    MORAB-202
    Sensitive
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    Small Intestinal Carcinoma
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    dMMR/MSI-H + TMB-L
    Small Intestinal Carcinoma
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    ER mutation
    Estrogen Receptor Positive Breast Cancer
    bevacizumab + paclitaxel
    Sensitive
    :
    C3
    ESMO-BC 2021 - 1wk
    ER positive + PGR positive
    HER2 Negative Breast Cancer
    tamoxifen
    Sensitive
    :
    C3
    ESMO-BC 2021 - 1wk
    HER-2 positive
    Gastric Cancer
    RC48
    Sensitive
    :
    C3
    Gastric Cancer - 1wk
    PD-L1 negative
    Melanoma
    pembrolizumab + ipilimumab
    Sensitive
    :
    C3
    J Clin Oncol - 1wk
    CIP2A-H
    CML
    imatinib
    Resistant
    :
    C3
    Cancers (Basel) - 1wk
    PIK3CA mutation
    HER2 Positive Breast Cancer
    trastuzumab + alpelisib + LJM-716
    Sensitive
    :
    C3
    Clin Cancer Res - 1wk
    BRAF V600K + CDKN2A deletion + RB1 expression
    Melanoma
    vemurafenib + palbociclib
    Sensitive
    :
    C3
    Clin Cancer Res - 1wk
    BRAF V600E + CDKN2A deletion + RB1 expression
    Melanoma
    vemurafenib + palbociclib
    Sensitive
    :
    C3
    Clin Cancer Res - 1wk
    RAD51 overexpression
    Ovarian Cancer
    PARP inhibitor
    Resistant
    :
    C3
    Cancer Cell Int - 1wk
    NF2 mutation
    Kidney Medullary Carcinoma
    bevacizumab + erlotinib
    Sensitive
    :
    C4
    Cancers (Basel) - 1wk
    NTRK1-KHDRBS1 fusion
    Sarcoma
    crizotinib
    Sensitive
    :
    C4
    World J Surg Oncol - 1wk
    MYC underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    HER-2 overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    FOXA1 overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    MIA underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    KRT5 underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    CDH3 underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    KRT17 underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    SFRP1 underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    CXXC5 overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    GPR160 overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    MLPH overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    GRB7 overexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    KRT14 underexpression
    Breast Cancer
    ribociclib
    Sensitive
    :
    D
    ESMO-BC 2021 - 1wk
    ARAF mutation + NRAS mutation
    Melanoma
    HM95573
    Resistant
    :
    D
    Nature - 1wk
    No biomarker
    Malignant Pleural Mesothelioma
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    Bristol-Myers Squibb Press Release - 2wk
    No biomarker
    AML
    azacitidine oral
    Sensitive
    :
    A1
    Bristol-Myers Squibb Press Release - 2wk
    No biomarker
    AML
    venetoclax
    Sensitive
    :
    A1
    Roche Press Release - 2wk
    No biomarker
    CLL
    zanubrutinib
    Sensitive
    :
    A1
    BeiGene Press Release - 2wk
    No biomarker
    Small Lymphocytic Lymphoma
    zanubrutinib
    Sensitive
    :
    A1
    BeiGene Press Release - 2wk
    No biomarker
    Triple Negative Breast Cancer
    sacituzumab govitecan-hziy
    Sensitive
    :
    A1
    N Engl J Med - 2wk
    No biomarker
    Diffuse Large B Cell Lymphoma
    loncastuximab tesirine
    Sensitive
    :
    A1
    FDA - 2wk
    No biomarker
    Urothelial Cancer
    pembrolizumab
    Sensitive
    :
    A1
    NICE - 2wk
    No biomarker
    RCC
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    No biomarker
    Cervical Cancer
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    No biomarker
    Ovarian Cancer
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    No biomarker
    GBM
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    No biomarker
    CRC
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    No biomarker
    Breast Cancer
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    No biomarker
    NSCLC
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    EGFR mutation
    NSCLC
    osimertinib
    Sensitive
    :
    A2
    Asia Pac J Clin Oncol - 2wk
    HER-2 negative
    HER2 Negative Breast Cancer
    eribulin mesylate
    Sensitive
    :
    A2
    Int J Clin Oncol - 2wk
    No biomarker
    Peritoneal Cancer
    bevacizumab + olaparib
    Sensitive
    :
    A2
    NICE - 2wk
    No biomarker
    Fallopian Tube Cancer
    bevacizumab + olaparib
    Sensitive
    :
    A2
    NICE - 2wk
    No biomarker
    Ovarian Cancer
    bevacizumab + olaparib
    Sensitive
    :
    A2
    NICE - 2wk
    EGFR exon 20 insertion
    NSCLC
    TAK-788
    Sensitive
    :
    B
    Takeda Press Release - 2wk
    CRLF2 rearrangement
    ALL
    ruxolitinib
    Sensitive
    :
    C2
    Leukemia - 2wk
    EGFR G719A
    NSCLC
    dacomitinib
    Sensitive
    :
    C2
    J Clin Oncol - 2wk
    HER-2 overexpression + PTEN deletion
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Resistant
    :
    C3
    Sci Rep - 2wk
    IDH2 mutation + SRSF2 mutation
    AML
    venetoclax
    Sensitive
    :
    C3
    Blood Adv - 2wk
    NRAS mutation + U2AF1 mutation
    AML
    venetoclax
    Resistant
    :
    C3
    Blood Adv - 2wk
    KRAS mutation + U2AF1 mutation
    AML
    venetoclax
    Resistant
    :
    C3
    Blood Adv - 2wk
    BTLA-H
    Solid Tumor
    Immunotherapy
    Resistant
    :
    C3
    Int J Cancer - 2wk
    CALR elevation
    NSCLC
    docetaxel
    Sensitive
    :
    C3
    Lung Cancer - 2wk
    CALR elevation
    NSCLC
    pemetrexed
    Sensitive
    :
    C3
    Lung Cancer - 2wk
    CALR elevation + EGFR mutation
    NSCLC
    osimertinib
    Sensitive
    :
    C3
    Lung Cancer - 2wk
    EGFR T790M + C797S
    LUAD
    gefitinib + osimertinib
    Resistant
    :
    C4
    Onco Targets Ther - 2wk
    EGFR T790M + C797S
    LUAD
    osimertinib + anlotinib
    Sensitive
    :
    C4
    Onco Targets Ther - 2wk
    HER-2 1899‐1G>A
    Gastric Adenocarcinoma
    trastuzumab
    Resistant
    :
    C4
    The Oncologist - 2wk
    BRCA1 mutation + TP53 R248Q
    Cervical Cancer
    bevacizumab + olaparib
    Sensitive
    :
    C4
    J Med Case Rep - 2wk
    GPRC5D overexpression
    Multiple Myeloma
    JNJ-64407564
    Sensitive
    :
    D
    Blood Adv - 2wk
    CD276 overexpression
    Triple Negative Breast Cancer
    B7H3-targeted CAR-T immunotherapy
    Sensitive
    :
    D
    ASGCT 2021 - 2wk
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Gastric Cancer
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Multiple Myeloma
    isatuximab-irfc
    Sensitive
    :
    A1
    Sanofi Press Release - 3wk
    PD-L1 overexpression
    NSCLC
    pembrolizumab
    Sensitive
    :
    A2
    J Clin Oncol - 3wk
    HER-2 positive
    HER2 Positive Breast Cancer
    TCH
    Sensitive
    :
    A2
    Ther Adv Med Oncol - 3wk
    EGFR mutation
    NSCLC
    erlotinib + ramucirumab
    Sensitive
    :
    A2
    Cancer Treat Res Commun - 3wk
    FGFR2b overexpression + HER2 negative
    Gastric Cancer
    FPA-144
    Sensitive
    :
    B
    Amgen Press Release - 3wk
    FGFR2b overexpression + HER2 negative
    Gastroesophageal Junction Adenocarcinoma
    FPA-144
    Sensitive
    :
    B
    Amgen Press Release - 3wk
    No biomarker
    Multiple Myeloma
    ALLO-715
    Sensitive
    :
    B
    Allogene Therapeutics Press Release - 3wk
    BRAF V600E
    Melanoma
    nivolumab + ipilimumab
    Sensitive
    :
    C2
    EADO-WCM 2021 - 3wk
    FLT3-ITD mutation
    AML
    quizartinib
    Sensitive
    :
    C2
    Haematologica - 3wk
    ER positive
    Estrogen Receptor Positive Breast Cancer
    tamoxifen + TAK-228
    Sensitive
    :
    C2
    Breast Cancer Res Treat - 3wk
    OLR1 overexpression
    NSCLC
    Immunotherapy
    Sensitive
    :
    C3
    Front Oncol - 3wk
    NRG1 overexpression
    Esophageal Squamous Cell Carcinoma
    AV-203
    Sensitive
    :
    C3
    Am J Cancer Res - 3wk
    BRAF mutation
    NSCLC
    PD-L1 inhibitor
    Sensitive
    :
    C3
    Eur J Cancer - 3wk
    EGFR exon 19 deletion
    NSCLC
    EGFR inhibitor
    Sensitive
    :
    C3
    Future Oncol - 3wk
    BRAF mutation
    NSCLC
    PD1 inhibitor
    Sensitive
    :
    C3
    Eur J Cancer - 3wk
    RB1 mutation + TP53 mutation
    Urothelial Cancer
    atezolizumab
    Sensitive
    :
    C3
    BMC Cancer - 3wk
    PTEN mutation
    Estrogen Receptor Positive Breast Cancer
    AZD5363
    Sensitive
    :
    C3
    NPJ Breast Cancer - 3wk
    CCNE1 overexpression
    Ovarian Cancer
    AZD1775
    Sensitive
    :
    C3
    Clin Cancer Res - 3wk
    CCNE1 overexpression
    Endometrial Cancer
    AZD1775
    Sensitive
    :
    C3
    Clin Cancer Res - 3wk
    XAGE1 antibody elevation
    NSCLC
    Immunotherapy
    Sensitive
    :
    C3
    Clin Chim Acta - 3wk
    CTAG1B antibody elevation + XAGE1 antibody elevation
    NSCLC
    Immunotherapy
    Sensitive
    :
    C3
    Clin Chim Acta - 3wk
    CTAG1B antibody elevation
    NSCLC
    Immunotherapy
    Sensitive
    :
    C3
    Clin Chim Acta - 3wk
    ASS1 negative
    HCC
    BCT-100
    Sensitive
    :
    C3
    Invest New Drugs - 3wk
    RAD52 underexpression
    Bladder Cancer
    cisplatin
    Resistant
    :
    C3
    Int J Mol Sci - 3wk
    BRAF V600E
    Melanoma
    Immunotherapy
    Resistant
    :
    C3
    SID 2021 - 3wk
    HER-2 amplification
    LUAD
    pembrolizumab
    Sensitive
    :
    C4
    Front Oncol - 3wk
    PD-L1 overexpression
    Thyroid Gland Anaplastic Carcinoma
    anlotinib + sintilimab
    Sensitive
    :
    C4
    Onco Targets Ther - 3wk
    WEE1 mutation + PKMYT1 overexpression
    Solid Tumor
    AZD1775
    Resistant
    :
    C4
    Clin Cancer Res - 3wk
    NRAS Q61R
    Melanoma
    nivolumab + ipilimumab
    Sensitive
    :
    C4
    EADO-WCM 2021 - 3wk
    NCOR2-NTRK1 fusion + TMB-H
    LUAD
    camrelizumab
    Resistant
    :
    C4
    BMC Pulm Med - 3wk
    NCOR2-NTRK1 fusion + TMB-H
    LUAD
    larotrectinib
    Sensitive
    :
    C4
    BMC Pulm Med - 3wk
    BRCA1 S451Lfs*20
    Gallbladder Cancer
    olaparib
    Sensitive
    :
    C4
    Onco Targets Ther - 3wk
    CD20 underexpression
    Multiple Myeloma
    lenalidomide
    Resistant
    :
    D
    Onco Targets Ther - 3wk
    TYRO3 mutation + ALK mutation
    Neuroendocrine Tumor
    sunitinib
    Sensitive
    :
    D
    Transl Oncol - 3wk
    BRAF V600E
    Melanoma
    encorafenib + S63845
    Sensitive
    :
    D
    EADO-WCM 2021 - 3wk
    NGFR overexpression
    Squamous Cell Skin Cancer
    5-fluorouracil
    Sensitive
    :
    D
    SID 2021 - 3wk
    NGFR overexpression
    Squamous Cell Skin Cancer
    cisplatin
    Sensitive
    :
    D
    SID 2021 - 3wk
    NRAS mutation
    Melanoma
    binimetinib + encorafenib
    Sensitive
    :
    D
    EADO-WCM 2021 - 3wk
    CD20 underexpression
    Multiple Myeloma
    elotuzumab
    Resistant
    :
    D
    Onco Targets Ther - 3wk
    TYRO3 mutation + ALK mutation
    Neuroendocrine Tumor
    crizotinib + sunitinib
    Sensitive
    :
    D
    Transl Oncol - 3wk
    TYRO3 mutation + ALK mutation
    Neuroendocrine Tumor
    crizotinib
    Resistant
    :
    D
    Transl Oncol - 3wk
    NEIL3 deletion
    Prostate Cancer
    enzalutamide
    Resistant
    :
    D
    Int J Mol Sci - 3wk
    No biomarker
    Multiple Myeloma
    pomalidomide + elotuzumab
    Sensitive
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive
    :
    A1
    CD20 positive
    CLL
    Truxima (rituximab biosimilar)
    Sensitive
    :
    C1
    EGFR exon 19 deletion
    NSCLC
    afatinib
    Sensitive
    :
    C1
    EGFR exon 19 deletion
    NSCLC
    osimertinib
    Sensitive
    :
    C1
    No biomarker
    NSCLC
    ramucirumab
    Sensitive
    :
    A1
    ALK positive
    NSCLC
    lorlatinib
    Sensitive
    :
    C1
    EGFR exon 19 deletion
    NSCLC
    gefitinib
    Sensitive
    :
    C1
    PD-L1 expression
    Triple Negative Breast Cancer
    atezolizumab
    Sensitive
    :
    C1
    EGFR L858R
    NSCLC
    afatinib
    Sensitive
    :
    C1
    EGFR T790M
    NSCLC
    osimertinib
    Sensitive
    :
    C1
    No biomarker
    NSCLC
    durvalumab
    Sensitive
    :
    A1
    ALK positive
    NSCLC
    alectinib
    Sensitive
    :
    C1
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + tucatinib
    Sensitive
    :
    C1
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + pertuzumab
    Sensitive
    :
    C1
    KIT positive
    GIST
    imatinib
    Sensitive
    :
    C1
    HER-2 positive
    HER2 Positive Breast Cancer
    margetuximab
    Sensitive
    :
    C1
    No biomarker
    RCC
    nivolumab + cabozantinib tablet
    Sensitive
    :
    A1
    PD-L1 expression
    NSCLC
    pembrolizumab
    Sensitive
    :
    C1
    ALK fusion
    NSCLC
    brigatinib
    Sensitive
    :
    C1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive
    :
    C1
    No biomarker
    Follicular Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Mediastinal B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES